Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors
Systimmune - Career Page
SystImmune 2026 Company Profile: Valuation, Funding & Investors | PitchBook
SystImmune and Bristol Myers Squibb Announce a Global Strategic ...
SystImmune and Bristol Myers Squibb Highlight Positive Phase III ...
SystImmune Doses First Patient in P-II/III (IZABRIGHT-Breast01) Trial ...
SystImmune and BMS’ Izalontamab Brengitecan Secures the US FDA’s ...
SystImmune and BMS Enter Exclusive Global Collaboration Agreement to ...
Systimmune Reviews | Glassdoor
Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/ ...
SystImmune Partners with Bristol-Myers Squibb to Develop and ...
SystImmune | LinkedIn
Systimmune - BL-M02D1-ADC - Antibody Drug Conjugates (ADC) Molecules By ...
SystImmune to Receive $250M Milestone Payment from Bristol Myers Squibb ...
SystImmune BL-B01D1-ADC Specificity Enhanced Bi-specific Antibody (SEBA ...
SystImmune Showcases Pivotal ADC Data at ESMO 2025, Strengthening Next ...
SystImmune Patents – Insights & Stats (Updated 2023) - Insights;Gate
SystImmune to Present iza‑bren (BL‑B01D1) Phase II ES‑SCLC Data at ELCC ...
SystImmune Receives $250M Milestone Payment from BMS | BMY Stock News
SystImmune and Bristol Myers Squibb Present First Global Phase I ...
SystImmune collaborates with Bristol Myers Squibb in a major worldwide ...
SystImmune Gets FDA Approval for BL-M17D1 IND Application for Advanced ...
Bristol Myers Squibb and SystImmune Receive FDA Breakthrough Status for ...
SystImmune 2025 Company Profile: Valuation, Funding & Investors | PitchBook
SystImmune Receives Milestone Payment from Bristol Myers Squibb Under ...
SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ...
FDA grants breakthrough status to Bristol drug with SystImmune for lung ...
SystImmune - News
SystImmune hits $250 million milestone as Bristol Myers backs pivotal ...
SystImmune 與必治妥施貴寶合作打造雙特異性 ADC 藥物 | GeneOnline News
Systimmune Announces SI-F019 As a Blocker of Viral Entry against ...
SystImmune Reaches Milestone in Triple Negative Breast Cancer Study ...
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal ...
ESMO Breast 2025: SystImmune to Present Izalontamab Brengitecan in ...
Leaders in Breast and Lung Cancer treatment join SystImmune Inc's ...
SystImmune 使用Solentim Cell Metric 单细胞克隆设备进行细胞系开发的方法 - 知乎
Bristol, SystImmune post trial win for breast cancer drug | Seeking Alpha
BMS bolts on SystImmune bispecific ADC in $8.4bn deal | pharmaphorum
SystImmune, Inc. to Present New Data from Oncology Programs at the ...
Systimmune, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
百利天恒全资子公司SystImmune任命Jie D’Elia博士为新任首席执行官医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
SystImmune, HQ & Research - LifeScienceHistory.com
Sichuan Biokin Pharmaceutical Co.,Ltd
百利天恒全资子公司SystImmune与百时美施贵宝就BL-B01D1的开发和商业化权益达成全球战略合作协议
SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical ...
SystImmune, Inc.
SystImmune's Milestone Payment from BMS: A Strategic Inflection Point ...
创始人半路出家，用10年投出一个价值600亿新药，吊打一众知名Biotech，它凭啥_财富号_东方财富网
Sichuan Biokin Pharmaceuticals Co.,Ltd
SystImmune, Inc. Announces FDA Clearance Of IND Application For BL ...
聚焦双抗ADC！SystImmune 的BL-B01D1 的 IND 申请获FDA批准 - 知乎
聚焦双抗ADC！SystImmune 的BL-B01D1 的 IND 申请获FDA批准|EGFR|HER2|HER3|IND|ADC|FDA ...
SystImmune: FDA Grants Breakthrough Therapy Designation For Iza-bren
FDA Approves SystImmune's IND Application for BL-M11D1 in Relapsed ...
SystImmune, Inc. Announces FDA Clearance of IND Application for BL ...
米SystImmune社とBMS社、EGFR・HER3二重特異性ADCの国際共同第I相の結果を発表：日経バイオテクONLINE
SystImmune, Inc. Announces First Patient Dosed in U.S. Phase 1 Clinical ...
SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren ...
Bristol Myers bags SystImmune’s lung cancer drug for $800M upfront in ...
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data ...
Bristol goes pivotal with SystImmune-partnered conjugate | ApexOnco ...
Systimmune, Inc. (Systimmune, Inc.) - 药物管线_专利_临床试验_投融营收_最新药物:BL-M07D1 ...
百利天恒双抗 ADC丨施贵宝首付款8亿美元已到账，加速创新 施贵宝凭借O药实现了肿瘤治疗领域的强势逆袭，但核心产品销量下降，网页链接 - 雪球
Bristol Myers Squibb to Pay Up to $8.4 Billion to Codevelop Antibody ...
聚焦双抗ADC！SystImmune 的BL-B01D1 的 IND 申请获FDA批准_腾讯新闻
BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast ...
Jackson Z. on LinkedIn: #careerupdate #newopportunities #systimmune # ...
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation ...
